DE60128239T2 - Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten - Google Patents

Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten Download PDF

Info

Publication number
DE60128239T2
DE60128239T2 DE60128239T DE60128239T DE60128239T2 DE 60128239 T2 DE60128239 T2 DE 60128239T2 DE 60128239 T DE60128239 T DE 60128239T DE 60128239 T DE60128239 T DE 60128239T DE 60128239 T2 DE60128239 T2 DE 60128239T2
Authority
DE
Germany
Prior art keywords
methyl
phenyl
alkyl
ethoxy
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128239T
Other languages
German (de)
English (en)
Other versions
DE60128239D1 (de
Inventor
Dawn Alisa Indianapolis BROOKS
Alexander Glenn Mooresville GODFREY
Sarah Beth Greenwood JONES
James Ray Zionsville MCCARTHY
Christopher John Martinsville RITO
Leonard Larry Greenwood WINNEROSKI
Yanping Fishers XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60128239D1 publication Critical patent/DE60128239D1/de
Application granted granted Critical
Publication of DE60128239T2 publication Critical patent/DE60128239T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DE60128239T 2000-08-23 2001-08-23 Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten Expired - Lifetime DE60128239T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
US227234P 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
DE60128239D1 DE60128239D1 (de) 2007-06-14
DE60128239T2 true DE60128239T2 (de) 2008-01-10

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128239T Expired - Lifetime DE60128239T2 (de) 2000-08-23 2001-08-23 Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten

Country Status (26)

Country Link
US (2) US6930120B2 (enExample)
EP (1) EP1313716B1 (enExample)
JP (1) JP2004506721A (enExample)
KR (1) KR20030027054A (enExample)
CN (1) CN1471517A (enExample)
AT (1) ATE361283T1 (enExample)
AU (1) AU2001284659A1 (enExample)
BR (1) BR0113409A (enExample)
CA (1) CA2418104A1 (enExample)
CY (1) CY1107679T1 (enExample)
CZ (1) CZ2003482A3 (enExample)
DE (1) DE60128239T2 (enExample)
DK (1) DK1313716T3 (enExample)
EA (1) EA200300286A1 (enExample)
EC (1) ECSP034504A (enExample)
ES (1) ES2286137T3 (enExample)
HU (1) HUP0300857A3 (enExample)
IL (1) IL154110A0 (enExample)
MX (1) MXPA03001558A (enExample)
NO (1) NO20030729L (enExample)
NZ (1) NZ523804A (enExample)
PL (1) PL360744A1 (enExample)
PT (1) PT1313716E (enExample)
SK (1) SK1872003A3 (enExample)
WO (1) WO2002016331A1 (enExample)
ZA (1) ZA200300570B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
ES2295200T3 (es) 2000-08-23 2008-04-16 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
ME01310B (me) * 2001-05-15 2011-10-10 Hoffmann La Roche Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
ATE372990T1 (de) 2002-07-03 2007-09-15 Hoffmann La Roche Oxazolderivat und deren verwendung als insulinsensibilisatoren
CN100475810C (zh) * 2002-08-30 2009-04-08 霍夫曼-拉罗奇有限公司 作为PPARα和PPARγ激动剂的新型2-芳基噻唑化合物
NZ537979A (en) 2002-09-12 2007-08-31 Hoffmann La Roche N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
ES2295692T3 (es) * 2002-11-08 2008-04-16 F. Hoffmann-La Roche Ag Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
MXPA05005445A (es) 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JP4767850B2 (ja) 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
CN100398536C (zh) * 2003-08-20 2008-07-02 爱密斯菲尔科技公司 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
US20080051418A1 (en) * 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
DE69723680T9 (de) 1996-02-02 2004-11-04 Merck & Co., Inc. Antidiabetische mittel
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
IL128600A0 (en) * 1996-08-19 2000-01-31 Japan Tobacco Inc Propionic acid derivatives and pharmaceutical compositions containing them
JP4345230B2 (ja) 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
DK1206457T3 (da) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
ES2295200T3 (es) 2000-08-23 2008-04-16 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.

Also Published As

Publication number Publication date
ES2286137T3 (es) 2007-12-01
CZ2003482A3 (cs) 2003-05-14
BR0113409A (pt) 2003-07-01
EP1313716B1 (en) 2007-05-02
HUP0300857A3 (en) 2007-03-28
IL154110A0 (en) 2003-07-31
US20050245584A1 (en) 2005-11-03
US6930120B2 (en) 2005-08-16
CY1107679T1 (el) 2013-04-18
NO20030729L (no) 2003-04-02
ECSP034504A (es) 2003-04-25
KR20030027054A (ko) 2003-04-03
DE60128239D1 (de) 2007-06-14
JP2004506721A (ja) 2004-03-04
ZA200300570B (en) 2004-04-21
AU2001284659A1 (en) 2002-03-04
HUP0300857A2 (hu) 2003-10-28
NZ523804A (en) 2004-09-24
NO20030729D0 (no) 2003-02-14
US20040097590A1 (en) 2004-05-20
MXPA03001558A (es) 2003-06-06
US7345070B2 (en) 2008-03-18
CN1471517A (zh) 2004-01-28
ATE361283T1 (de) 2007-05-15
PT1313716E (pt) 2007-07-11
SK1872003A3 (en) 2003-07-01
DK1313716T3 (da) 2007-08-27
EA200300286A1 (ru) 2003-08-28
WO2002016331A1 (en) 2002-02-28
EP1313716A1 (en) 2003-05-28
PL360744A1 (en) 2004-09-20
CA2418104A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE60129712T2 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
DE60216094T2 (de) Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar)
DE60005973T2 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE60315603T2 (de) Modulatoren von peroxisome proliferator-aktivierten rezeptoren
DE60132799T2 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
DE602004011985T2 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
DE68905639T2 (de) Hypoglykaemische thiazolidindion-derivate.
AU645112B2 (en) Hypoglycemic hydroxyurea derivatives
JP4436129B2 (ja) ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用
DE602004010889T2 (de) Sulfonamid-derivate als ppar-modulatoren
AU2003209676B2 (en) Phenyl(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity
JP2005517643A (ja) ペルオキシソーム増殖因子活性化受容体アゴニスト
DE60131001T2 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
EP1313716B1 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
DE10308355A1 (de) Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7220880B2 (en) Amide linker peroxisome proliferator activated receptor modulators
US7446127B2 (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP3966693B2 (ja) 含窒素環化合物およびそれらを含んでなる医薬組成物

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336